Cipla soars on inking agreement with Novartis Pharma AG!

Cipla soars on inking agreement with Novartis Pharma AG!

by 5paisa Research Team Last Updated: Apr 10, 2023 - 06:06 pm 683 Views
Listen icon

The pharma stock was buzzing on the bourses today.  

License Agreement with Novartis Pharma AG

Cipla signed a perpetual license agreement with Novartis Pharma AG (Switzerland) on April 10, 2023, to manufacture and market Galvus and Galvus combination brands, used in the treatment of type 2 diabetes from January 1, 2026. The agreement is subject to satisfaction of certain conditions precedent. During the interim period, it would continue to market and distribute Galvus-branded products.

Galvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication category. Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs 268 crore (IQVIA MAT February 2023). This deal is expected to further bolster Cipla’s position in India as one of the top players in the diabetes category.

Share price movement of Cipla Limited

Today, the stock opened at Rs 895.10, with a high and low of Rs 904.05 and Rs 894.50. The stock closed trading today at Rs 901.85, up by 1.02%.

The stock has a 52-week high of Rs 1185 and a 52-week low of Rs 852. The company has a market capitalisation of Rs 72,792.88 crore.

Company profile  

Cipla Limited is a global pharmaceutical company focused on the responsible and sustainable growth of complex generics and deepening its portfolio in home markets of India, South Africa and North America, as well as key regulated and emerging markets. The company is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).

Share Market Today

How do you rate this article?


Start Investing in 5 mins*

Rs. 20 Flat Per Order | 0% Brokerage


About the Author

Our research team is composed of some highly qualified research professionals, their expertise range across sectors.


Investment/Trading in securities Market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equites and Derivatives can be substantial.
Open Free Demat Account
Resend OTP
Please Enter OTP
Mobile No. belongs to

By proceeding, you agree to the T&C.

Latest News
Revving Up: Catch the Exciting November 2023 Auto Sales Highlights!

Escorts Kubota Ltd. witnessed a 4% increase in its total dispatches to dealerships, reaching 8,258 units, reflecting a 3.7% YoY growth. The rise in total dispatches to dealerships for Escorts Kubota Ltd.

Dixon Technologies to Manufacture Xiaomi Phones at Noida Plant

In a transformative move to enhance local smartphone manufacturing, Dixon Technologies (India) Ltd. has inaugurated a smartphone manufacturing plant in Noida.

JSW Group acquires 35% in MG Motor India, a SAIC subsidiary

On November 30, JSW Group announced a joint venture (JV) with SAIC Motor Corp. Ltd, the parent company of MG Motor India.